Tumour, site | Animal | VAE |
Tumour growth T/C (%) | Survival | Other outcomes | Reference |
---|---|---|---|---|---|---|
Human breast tumour | ||||||
Breast | Mice | rML 0,3 ng/kg – 3 μg/kg, ip, qd * 5 * 2–4 w | No effect | [129] | ||
Murine breast tumour in mice | ||||||
C3L5, adenocarcinoma; sc | Mice (C3H7HeJ) | ML I, 1 ng/kg, sc, q3d, day 7–19 | 160 | 27.6 lung-metastases | [130] | |
IL-2, twice 6 × 104 IU/mouse, ip q8h 2 * qd * 5 | 43 | 2.3 lung-metastases | ||||
Combination of ML 1 & IL-2 | 37 | 2.3 lung-metastases | ||||
Control | 7.5 lung-metastases | |||||
ECa, ip | Mice (ICR) | ML I, 80 ng, ip, day 1 | 70% died after 50 days | [131] | ||
A-chain of ML I, 100 μg, ip, day 1 | 80% died after 57 days | |||||
B-chain of ML I, 10 μg, ip, day 1 | 80% died after 58 days | |||||
Control | 100% died after 20 days | |||||
ECa, sc | Mice (BALB/c) | VAE 5 kDa peptides, 2 μg, it, day 7 | Severe necrosis, infiltration of lymphocytes and macrophages | [122] | ||
ECa, ip | Mice (CD-1) | Vester' Proteins, ip, 0.1 or 1 or 10 μ/kg, qd * 10 | ILS: 0, 33, and -33%I | [132] | ||
ECa | Mice | Polysaccharide („Viscumsäure“), ip, qd * 6 | Slight effect | [133] | ||
Adenocarcinoma EO 771 | Mice | Polysaccharide („Viscumsäure“), ip, qd * 6 | Moderate effect | [133] | ||
Murine breast tumour in rats | ||||||
Walker Carcinosarcoma | Rats | Polysaccharide („Viscumsäure“), ip, qd * 6 | Moderate effect | [133] | ||
Other gynaecological tumour | ||||||
Ovary, SoTü 3, ip | Mice (SCID) | rML 30 ng/kg, ip, qd * 5 * 12 | 35% mice alive at day 84 | 40% tumour-free mice at day 84 | [134] | |
rML 150 ng/kg, ip, qd * 5 * 12 | 10% mice alive at day 84 | 10% tumour-free mice at day 84 | ||||
rML 500 ng/kg, ip, qd * 5 * 12 | 75% mice alive at day 84 | 65% tumour-free mice at day 84 | ||||
Control | 15 mice alive at day 84 | 10% tumour-free mice at day 84 | ||||
Uterusepithelioma T-8 Guérin | Rats | Polysaccharide ("Viscumsäure"), ip, qd * 6 | Moderate effect | [133] |